TargetMol

9-CP-Ade Mesylate

Product Code:
 
TAR-T23588
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T23588-1mg1mg£140.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23588-5mg5mg£242.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23588-10mg10mg£322.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23588-25mg25mg£495.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23588-50mg50mg£686.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
9-CP-Ade Mesylate is a Cell-permeable and non-competitive inhibitor of adenylyl cyclase.
CAS:
189639-09-6
Formula:
C11H17N5O3S
Molecular Weight:
299.35
Pathway:
Neuroscience
Purity:
0.98
SMILES:
CS(O)(=O)=O.Nc1ncnc2n(cnc12)C1CCCC1
Target:
AChR

References

Denda M, et al. Association of cyclic adenosine monophosphate with permeability barrier homeostasis of murine skin. J Invest Dermatol. 2004 Jan;122(1):140-6. Idrizaj E, et al. Relaxin influences ileal muscular activity through a dual signaling pathway in mice. World J Gastroenterol. 2018 Feb 28;24(8):882-893. Riese U, et al. Militarinone A induces differentiation in PC12 cells via MAP and Akt kinase signal transduction pathways. FEBS Lett. 2004 Nov 19;577(3):455-9.